Cellular Tumor Antigen p53 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)- Pipeline Review, H2 2019’, provides in depth analysis on Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology and Toxicology under development targeting Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

– The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Actavalon Inc

ADRx Inc

Affina Biotechnologies Inc

Aprea Therapeutics AB

BlinkBio Inc

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ISA Pharmaceuticals BV

LynkCell Inc

MultiVir Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Pharos I&BT Co Ltd

PMV Pharmaceuticals Inc

Quark Pharmaceuticals Inc

Shenzen SiBiono GeneTech Co Ltd

SynerGene Therapeutics Inc

Tara Immuno-Oncology Therapeutics LLC

Z53 Therapeutics LLC”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Overview

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Companies Involved in Therapeutics Development

Actavalon Inc

Aprea AB

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Drug Profiles

APR-246 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-14022 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBS-9106 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contusugene ladenovec Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYN-00103 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MHY-449 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MJ-05 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Viruses to Activate p53 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPAL-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate p53 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate p53 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology and Viral Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cellular Tumor Antigen p53 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZMC-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Dormant Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Discontinued Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Product Development Milestones

Featured News & Press Releases

Jul 09, 2018: Quark Pharmaceuticals Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Jul 05, 2018: OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

Jul 02, 2018: OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi

Jun 17, 2018: Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

Jun 05, 2018: Stemline Therapeutics Announces Positive Data Presentations on SL-801 at ASCO

May 24, 2018: Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program

May 17, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting

May 17, 2018: Stemline Therapeutics Announces Presentation of SL-801 Clinical Data at the Upcoming ASCO Annual Meeting

Apr 26, 2018: Stemline Therapeutics Announces Clinical Presentation of SL-801 at the Upcoming ASCO Annual Meeting

Apr 16, 2018: Karolinska Development's portfolio company Aprea presents initial results from the ongoing phase Ib/II study with APR-246 and azacitidine for the treatment of Mutant Myelodysplastic Syndromes

Apr 03, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Mar 26, 2018: Combination breast cancer therapy targets both tumor cells and the blood vessels that supply them, MU researchers find

Mar 20, 2018: Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs

Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Actavalon Inc, H2 2019

Pipeline by ADRx Inc, H2 2019

Pipeline by Affina Biotechnologies Inc, H2 2019

Pipeline by Aprea Therapeutics AB, H2 2019

Pipeline by BlinkBio Inc, H2 2019

Pipeline by CanBas Co Ltd, H2 2019

Pipeline by Cotinga Pharmaceuticals Inc, H2 2019

Pipeline by Innovation Pharmaceuticals Inc, H2 2019

Pipeline by ISA Pharmaceuticals BV, H2 2019

Pipeline by LynkCell Inc, H2 2019

Pipeline by MultiVir Inc, H2 2019

Pipeline by ORCA Therapeutics BV, H2 2019

Pipeline by OSE Immunotherapeutics, H2 2019

Pipeline by Pharos I&BT Co Ltd, H2 2019

Pipeline by PMV Pharmaceuticals Inc, H2 2019

Pipeline by Quark Pharmaceuticals Inc, H2 2019

Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2019

Pipeline by SynerGene Therapeutics Inc, H2 2019

Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2019

Pipeline by Z53 Therapeutics LLC, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Dormant Products, H2 2019 (Contd..3), H2 2019

Dormant Products, H2 2019 (Contd..4), H2 2019

Dormant Products, H2 2019 (Contd..5), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports